Viking Therapeutics Options Transactions Indicate Bullish Trends
Viking Therapeutics Shows Unusual Options Activity
Recently, an intriguing wave of trading activity has emerged for Viking Therapeutics, revealing how financial giants are backing the stock. In our recent examination of options trading for Viking Therapeutics (VKTX), we uncovered a total of nine unusual trades that highlight this bullish trend.
Diving deeper into the statistics, the analysis indicates that 55% of traders displayed a bullish sentiment, while 44% leaned bearish. Notably, the trades consisted of two puts valued at $353,060 and seven calls amounting to $317,256.
Insight into Predicted Price Levels
Examining the volume and open interest associated with these options, it appears the major market players are forecasting a price range between $20.0 to $50.0 for Viking Therapeutics in the upcoming quarter. This anticipated window may present trading opportunities for those keeping a close watch.
Tracking Volume and Open Interest Developments
In the realm of options trading, understanding volume and open interest is essential. This data enables traders to gauge the market’s liquidity and the level of interest that Viking Therapeutics’ options hold across various strike prices. Below are the notable changes regarding the volume and open interest of calls and puts associated with the recent larger trades, specifically focusing on the price range of $20.0 to $50.0 over the past month.
Key Options Trades for Viking Therapeutics
Some significant options trades have been recorded for Viking Therapeutics:
Significant Trades:
- Symbol: VKTX
Type: PUT
Trade Type: SWEEP
Sentiment: BULLISH
Expiration: 08/15/25
Ask: $2.89
Bid: $2.56
Price: $2.70
Strike Price: $20.00
Total Trade Value: $270,200
Open Interest: 183
Volume: 1 - Symbol: VKTX
Type: CALL
Trade Type: SWEEP
Sentiment: BULLISH
Expiration: 04/17/25
Ask: $2.34
Bid: $1.93
Price: $1.93
Strike Price: $32.50
Total Trade Value: $91,300
Open Interest: 345
Volume: 501 - Symbol: VKTX
Type: PUT
Trade Type: TRADE
Sentiment: BULLISH
Expiration: 01/16/26
Ask: $11.35
Bid: $9.30
Price: $9.74
Strike Price: $30.00
Total Trade Value: $82,700
Open Interest: 821
Volume: 85 - Symbol: VKTX
Type: CALL
Trade Type: SWEEP
Sentiment: BEARISH
Expiration: 03/21/25
Ask: $1.68
Bid: $1.50
Price: $1.50
Strike Price: $30.00
Total Trade Value: $56,500
Open Interest: 2,100
Volume: 410 - Symbol: VKTX
Type: CALL
Trade Type: SWEEP
Sentiment: BEARISH
Expiration: 01/15/27
Ask: $7.35
Bid: $6.50
Price: $6.70
Strike Price: $50.00
Total Trade Value: $51,500
Open Interest: 755
Volume: 86
About Viking Therapeutics
Viking Therapeutics Inc is dedicated to advancing healthcare through innovative biopharmaceutical developments targeting metabolic and endocrine issues. The company's pipeline includes promising candidates like VK2809, VK5211, and VK0214, all designed to tackle various health conditions effectively.
Current Market Position for Viking Therapeutics
- The most recent trading volume stands at 1,697,510 but has seen a drop of -6.69%, with the current price at $26.94.
- Recent RSI indicators suggest the stock may be nearing oversold conditions.
- The earnings release date approaches in about 51 days.
Analyst Perspectives on Viking Therapeutics
In summary, a group of five market analysts recently evaluated the stock, establishing a consensus target price of $99.2.
One analyst from Piper Sandler continues to advocate a robust Overweight rating for Viking Therapeutics, projecting a price target of $71.
Similarly, Scotiabank's analyst has moderated their rating to Sector Outperform with an adjusted target of $102.
Meanwhile, HC Wainwright & Co. has upgraded their rating to Buy with a price target held at $102.
Notably, Raymond James maintains a Strong Buy rating on Viking Therapeutics, forecasting a target price of $125.
B. Riley Securities has recently downgraded to a Buy recommendation with a target of $96.
While trading options presents inherent risks compared to simple stock trading, they offer substantial profit opportunities for astute traders. Successful options traders emphasize ongoing education, strategic entry and exit of trades, and keen market observation to effectively manage risks.
If staying informed on the latest options transactions for Viking Therapeutics is your goal, numerous resources provide current alerts on trades.
Frequently Asked Questions
1. What is the current trading status of Viking Therapeutics?
As of now, Viking Therapeutics is trading at $26.94, having decreased by 6.69% recently.
2. What are the major products developed by Viking Therapeutics?
The company's pipeline includes VK2809, VK5211, and VK0214, focusing on metabolic and endocrine disorders.
3. What do analysts predict for Viking Therapeutics?
Analysts have a consensus target price of $99.2 for Viking Therapeutics, with various ratings from different firms.
4. What type of options activity has been noticed for Viking Therapeutics?
Recent analysis revealed predominately bullish activity, with a significant number of call options and moderate put options trades.
5. How can one stay updated on Viking Therapeutics options trading?
Consider subscribing to real-time options trading alerts through specialized platforms to keep informed on the latest trades.
About The Author
Contact Kelly Martin privately here. Or send an email with ATTN: Kelly Martin as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
